If you have a genetic report which you would like interpreted, we use Opus23 Explorer software to curate reports using other genetic platforms (Ancestry and 23andme combined) which are no longer clinically relevant on their own due to the limited information on key single nucleotide polymorphisms (SNPs) available.
Opus23 uses the latest medical literature to provide relevant information on nutraceuticals, nutritional supplements, diet, and lifestyle interventions that can proactively influence a patient’s SNPs to reduce or prevent disease risk. Furthermore, pharmacogenomic results included in the profile allow practitioners to predict the efficacy of select pharmaceuticals tailored the individual’s genetic make-up which can be extremely valuable for targeted therapies such as chemotherapy.
Results include therapeutic recommendations backed by the latest medical literature from PubMed, GWAS (genome wide association study), dbSNP, HapMap (haplotype map) and several others.
Key Evaluation Areas Include (but are not limited to):
The role of genomics and epigenetics is recognised as an important tool in monitoring, preventing, and treating dysfunction. Furthermore, medical literature supports that epigenetics (the impact of the environment on gene expression) plays a critical role in human health. Opus23 Explorer allows the construction of algorithms, which identify clusters of SNPS which may impact expression of specific genes.
This fee includes a detailed analysis and personalised report, an assessment form to review current state of health, and a 45 minute telephone or video consultation to review findings and discuss recommendations.